1. Home /
  2. Investing /
  3. Cannabis


Plus Cannabis Gummies Get a 'Speculative Buy' Rating With a Delicious Outlook

If Plus cannabis gummies are a big hit, just think how consumers will respond to hemp-derived CBD gummies.

Cause for Caution? Top Executives Selling Tilray Stock

It might not be time to panic yet about Tilray, but there's likely a problem ahead.

With Tilray, You Won't Win Any Valuation Arguments

Short interest is back in the low single digits while Tilray still enjoys one of the smallest floats for a cannabis company.

Another Hemp Play to Consider: Charlotte's Web Holdings

Investors looking for another hemp play might consider Charlotte's Web Holdings, which deals in a range of CBD wellness products.

Tilray Touts Global Ambition as Erosion of Canadian Market Expected

A key aspect of the international expansion is the company's recent acquisition of hemp-food producer Manitoba Harvest in February.

Tilray Is Not My Favorite Canadian Cannabis Stock

Apparently, this game is all about growth right now. It certainly is not about margins.

Kass: Tilray Is Promising but I Prefer This Other Stock in the Pot Space

Tilray will not be cash flow positive for another 2-3 years - that's not quick enough progress for me given its $7 billion dollar capitalization.

Tilray Has Rebased and Looks Poised to Rally Again - Consider Buying Strength

Let's check out the charts and indicators for this so-called pot play.

Tilray Stock Lights Up as Partnerships Obscure Profitability Problem

The move was helped by the TLRY's deals with AB InBev for beverages and Novartis for medical applications.

CannTrust Is on the Verge of a Breakout Move: How to Play This Cannabis Stock

Recently uplisted CTST is a huge player in the medical marijuana market.

2 Hemp Stocks for Investors Looking for Something Different

You may want to check out GW Pharmaceuticals and Elixinol Global Limited.

3 Important Earnings Reports I'll Be Watching This Week

This quarter is a heavy test for Tilray because of the stock's lofty valuation.

Chart of the Day: Vetting the Value of Cannabis Companies

Assessing Aurora and its peers, strictly on the numbers.

Peltz Is the Perfect Problem Solver for Aurora Cannabis

Peltz's addition should pacify a persistent critique of the company.

Aurora Cannabis' Is a Beast but the Stock Has Entered a Tricky Area Now

Aurora Cannabis' hiring of deal maker Nelson Peltz opens up a wealth of new possibilities for the Canadian pot company.

Jim Cramer: Buy Aurora Cannabis Because Nelson Peltz Knows What Can Go Right

I know that Nelson is fascinated by the medicinal properties chiefly as a replacement for opioids, the scourge of this country.

Nelson Peltz Could Be Key to Cannabis in Consumer Packaged Goods

Aurora's prominent partner could be cannabis' key to breaking into consumer segments.

Aurora Cannabis Builds Momentum, Enter Nelson Peltz

The plan is for Peltz to help the firm in maximizing potential markets to target.

Aurora Cannabis, Nelson Peltz, and the Move For Acquisitions

Themes like cannabis tend to persist longer than many think they will.

Aurora Cannabis Could Triple in the Months Ahead

The price of ACB is moving up today and a fresh look at the charts and indicators seems like a good idea.

Aurora Cannabis Stock Burns Higher After Adding Billionaire Advisor Peltz

Aurora's addition of a big name activist is accelerating share growth.

Seaport's 4 Best Picks in Cannabis

This $12 billion industry could rise to around $630 billion over time, according to Seaport analysts.

Pyxus International: Here's a Way to Trade the Cannabis Stock

Potential buyers are faced with a small dilemma here.

Positive Breadth Helps Momentum Continue Despite Boeing's Woes

Strength in Apple and other FANG names are pluses, as are pockets of action in gold mining, cannabis, biotechnology and shipping.

Melius Research Launches Cannabis Industry Coverage

In its first report on cannabis companies, Melius says prices are high.

Two Months Into 2019, It's Time To Take Stock of My Winners and Losers

And the winners so far outnumber the losers among the six stocks that include a cannabis company, a couple financial giants and two oil plays.

Can Cronos Group Soar Higher? Looks Like it

The stock price of the cannabis company has been on a roll and is poised to move even higher still.

GW Pharmaceuticals Is Ready to Rally More: How to Trade This Cannabis Stock

My trading strategy for GWPH whether you are currently long or want to be.

Jim Cramer: My Best Stock Picks for Cannabis and China

And why I won't recommend any other stocks in these markets, right now.

Canaccord Gives Customer CLS Holdings a Speculative Buy Rating

CLS Holdings USA has won a speculative buy rating from Canaccord, but the cannabis company will have to raise $56 million to complete some key acquisitions in order to keep it.